

## Disclosures

### Personal Commercial (26)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<b><i>Self</i></b>			
Amgen	Research/Research Grants	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Amgen	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
AstraZeneca	Research/Research Grants	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies Prevention</i>
AstraZeneca	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies Prevention</i>
Baxter Healthcare	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Bayer AG	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies Prevention</i>
Boehringer Ingelheim Pharmaceuticals, Inc	Research/Research Grants	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies Prevention</i>
Boehringer Ingelheim Pharmaceuticals, Inc	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies Prevention</i>
Cytokinetics	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Esperion	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>General Cardiology</i>
Fresenius Medical Care	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>General Cardiology</i>
Galmed	Research/Research Grants	Modest (< \$5,000)	<i>Prevention</i>
Idorsia	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>General Cardiology</i>
Impulse Dynamics	Research/Research Grants	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Lexicon Pharmaceuticals	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies Prevention</i>
Merck & Co., Inc.	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Milestone Pharmaceuticals	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>General Cardiology</i>
Novartis Corporation	Research/Research Grants ‡ VICTORION-NOVEL	Significant (>= \$5,000)	<i>Prevention</i>
Novartis Corporation	Speaker's Bureau	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Occlutech	Research/Research Grants	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Recordati	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Relypsa	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Roche Diagnostics	Speaker's Bureau	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Sanofi-Aventis	Research/Research Grants	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Sanofi-Aventis	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Tricog Health	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (0)

No disclosures on record

### Clinical Trial Enroller (0)

No disclosures on record

## Institutional Financial Decision-Making Role (0)

No disclosures on record

## Expert Witness Testimony (0)

No disclosures on record

<sup>†</sup> Commercial Funding Source | <sup>‡</sup> Trial Name

## Agreement

### **Certified Education Attestation** | Signed on 10/23/2025

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>*

### **Confidentiality, Disclosure and Assignment Agreement** | Signed on 10/23/2025

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>*

### **Embargo** | Signed on 10/23/2025

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>*

### **On-Going Obligation Agreement** | Signed on 10/23/2025

## ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.